Modified growth-hormone-releasing peptide · Fact sheet
Modified GRF (1–29)
Also known as CJC-1295 without DAC · CJC-1295 no DAC · Mod GRF 1-29
Modified GRF (1–29), often called CJC-1295 without DAC, is discussed as a shorter-acting growth-hormone-releasing peptide. Published long-acting CJC-1295 studies cannot establish its own dosing, duration or recovery benefits.
What is Modified GRF (1–29)?
GRF is growth-hormone-releasing factor. The no-DAC name distinguishes material without the albumin-binding drug-affinity complex.
The published CJC-1295 development papers describe an albumin-binding molecule; removing that feature changes the formulation being evaluated.
Benefits & claims
Readers often encounter this name in ipamorelin combinations. A plausible interaction between hormone pathways is not proof of improved strength, sleep or body composition.
What the evidence supports
- The albumin-binding CJC-1295 trial increased GH and IGF-1 in healthy adults. That result concerns hormone measurements and the DAC molecule.
- Neither a half-life nor a regimen from the DAC study can be transferred to this no-DAC entry.
Research areas
- Growth-hormone signaling
- GHRH analog structure
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Modified GRF (1–29). Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- GRF is growth-hormone-releasing factor. The no-DAC name distinguishes material without the albumin-binding drug-affinity complex.
Formulation differences
- No-DAC products should not inherit the 5.8–8.1-day half-life reported for albumin-binding CJC-1295.
- A blend containing a no-DAC ingredient is a different exposure from either ingredient alone.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Human pharmacokinetics of a chemically verified no-DAC product
- Clinical outcomes beyond hormone measurements
- Long-term metabolic effects
Side effects & risks
- The exact identity, impurity profile and immunogenic potential of nonstandard peptide preparations may vary.
- FDA reports increased heart rate and systemic vasodilatory reactions associated with CJC-1295; the frequency for an exact no-DAC product is unestablished.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe cited primary papers characterize albumin-binding CJC-1295. They support the identity distinction, not a clinical efficacy claim for no-DAC products.
Studies
Rat and laboratory development paper detailing the reactive albumin-binding group.
Human study of the albumin-binding analog; not evidence for no-DAC products.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
There is no FDA-approved Modified GRF (1–29) product for recovery or wellness. FDA safety findings for CJC-1295 do not validate products sold with a no-DAC name.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Human pharmacokinetics of a chemically verified no-DAC product
- Clinical outcomes beyond hormone measurements
- Long-term metabolic effects
Summary
Neither a half-life nor a regimen from the DAC study can be transferred to this no-DAC entry.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedIdentification of albumin-binding CJC-1295
Rat and laboratory development paper detailing the reactive albumin-binding group.
- pubmedLong-acting CJC-1295 in healthy adults
Human study of the albumin-binding analog; not evidence for no-DAC products.
- fdaFDA: safety concerns for nominated bulk substances
Ingredient-specific uncertainties; compounding consideration is separate from FDA drug approval.